Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?

Diabetes Technol Ther. 2016 Nov;18(11):671-673. doi: 10.1089/dia.2016.0339.

Author

Richard E Pratley¹

Affiliation

¹ Translational Research Institute for Metabolism and Diabetes, Florida Hospital Diabetes Institute, Sanford Burnham Prebys Medical Discovery Institute , Orlando, Florida.

PMID: 27860501
DOI: 10.1089/dia.2016.0339

No abstract available

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / etiology
Glucagon-Like Peptide-1 Receptor / agonists*
Humans
Hypoglycemic Agents* / adverse effects
Hypoglycemic Agents* / therapeutic use
Metformin / therapeutic use

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Metformin